Navigation Links
ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
Date:12/16/2009

hase II study evaluating microplasmin in patients with AMD.

The primary endpoint of both of the MIVI-TRUST trials is the non-surgical resolution of focal vitreomacular adhesion after one month. This anatomical endpoint is being measured and recorded using Optical Coherence Tomography (OCT) which provides images that can clearly show the separation of the vitreous from the retina. OCT is a very sensitive and specific method for detecting the resolution of focal vitreomacular adhesion. In addition to the primary endpoint, the Phase III trials will evaluate additional measures of efficacy as well as safety, assessed at various time periods over the six month study period.

It is expected that the results from the first microplasmin Phase III study, the TG-MV-006 study will be presented in Q2 2010 and the results from the TG-MV-007 study in Q3 2010.

Dr. Patrik De Haes, CEO of ThromboGenics commented, "We are very pleased to announce that we have completed enrolment of our second pivotal Phase III trial for microplasmin, ahead of schedule. Microplasmin is key to the success of our ophthalmic focused strategy and the speed at which patients have been recruited is encouraging. We very much look forward to announcing the first results from our MIVI-TRUST Phase III program by mid 2010."

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagu
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
9. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
10. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015   EVO Aesthetic ... the leading provider for non-invasive aesthetics in ... tattoo removal treatments with the Astanza Duality laser. The ... well being through various medical and laser procedures. Their ... unwanted ink a clear solution to their tattoo regret. ...
(Date:7/2/2015)... ROCKY HILL, Conn. , July 2, 2015 /PRNewswire/ ... , Chief Executive Officer announced that Tamas Feitel ... Feitel joins Numotion after a highly successful ... global finance leadership roles driving strategy, profitability, and productivity ... generation. His most recent position was Chief Financial Officer ...
(Date:7/2/2015)... 2015   Decision Resources Group finds ... less frequent dosing as the highest unmet need ... burden on both patients and providers associated with ... injections, which are the current standard of care. ... is in development for dosing every two to ...
Breaking Medicine Technology:EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Numotion Names Tamas Feitel Chief Financial Officer 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3
... Mass., Oct. 20, 2011 Boston Scientific Corporation (NYSE: ... 30, 2011, as well as updated sales and earnings per share ... Third quarter and other highlights: ... per share and adjusted EPS of $0.15, both exceeding previous guidance ...
... 20, 2011 OncoSec Medical Incorporated (OTCBB: ONCS), which ... treatment of solid tumor cancers, announced today the submission ... Food and Drug Administration (FDA) for its patented ... generator and hand-held applicator. The Company has been developing ...
Cached Medicine Technology:Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 2Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 3Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 4Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 5Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 6Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 7Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 8Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 9Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 10Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 11Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 12Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 13Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 14Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 15Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 16Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 17Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 18Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares 19Device Master File for OncoSec Medical System Completed and Submitted to FDA 2Device Master File for OncoSec Medical System Completed and Submitted to FDA 3
(Date:7/3/2015)... ... July 03, 2015 , ... Smoothies are all the rage ... blender and easily accessible, quality ingredients. Aurora Natural is proud to introduce a new ... boost of fiber, protein, antioxidants, vitamins and minerals! , Aurora is offering a variety ...
(Date:7/3/2015)... ... July 03, 2015 , ... First Choice Emergency Room ... Mariah N. Manzanares, MD as the new Medical Director of its Frisco facility. , ... of our Frisco facility,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:7/3/2015)... ... 03, 2015 , ... Every year, One-to-1 Fitness and the Red Deer ... the Red Deer community with free fitness training and indoor fitness boot camp classes ... and entertainment raised thousands of charity dollars and ended with a $10,000 donation to ...
(Date:7/2/2015)... ... ... LLC. is pleased to announce the opening of its newest location in Dallas, Texas. The ... frozen yogurt chain was listed as #22 on the Inc. 500 list of fastest growing ... Lake, is located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 , “We ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... Donna Edwards (D-Md.) for her introduction of the Stop Overdose Stat (S.O.S.) Act ... by Senator Jack Reed (D-R.I.), this Act seeks to decrease drug overdose – ...
Breaking Medicine News(10 mins):Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3
... diseases of all types in the state. ... contagious and non-contagious diseases in the state under the integrated ... told IANS. ,He said the five-year project ... work and immediate control of natural calamities. ...
... world fashion map, it is attracting international models who ... but also try their luck in Bollywood. ... stopped copying Western motifs blindly. India emerged as a ... profitable business destination for international buyers. ,Indian ...
... University researchers say that a single drug for keeping ... 2 diabetes under check may soon be available. ... of Medicine and Pharmacology at Tulane University School of ... with Sulfonylurea-based therapy has been found to significantly reduce ...
... People with normal cognitive functions may be vulnerable to ... lobe or damage to blood vessels in the ... ,The study, published in the Journal of Neuroimaging, ... more likely to develop the disease than their peers. ...
... the genetic factors that make some mosquitoes resistant to ... mosquitos immune system is the key to their finding. ... that causes malaria, a biochemical reaction is triggered that physically ... to the parasites surface and targeting it for termination, they ...
... be a serious catalyst of global change. Its effects ... insect-plant food chain link.Safeguarding highly-usable crops is of great ... research to be presented at the annual meeting of ... 7-11, 2007), scientists will show that elevated CO2 may ...
Cached Medicine News:Health News:Indian Fashion Beckons International Models 2Health News:Genetic Factors Behind Mosquitoes Resistance to Malaria Identified 2Health News:Elevated Carbondioxide may Have Negative Impact on Ecosystem 2
... generation access device - XPOSE 4 - ... The XPOSE 4 Device is designed to ... surgery and to easily position and access ... both apical and non-apical placement on the ...
... ACROBAT SUV vacuum stabilizer from Guidant. ... ease of use. The newest members of ... stability with outstanding anastomotic site visibility ... our FlexLink technology on a stronger ...
... in 1992, ABIOMED's BVS 5000 has grown to ... system in the world to support recoverable hearts. ... U.S. Food and Drug Administration for all patients ... to make advances with the BVS 5000, expanding ...
... Dissector has application for use in the ... extraperitoneal spaces such as the retroperitoneal, preperitoneal, ... used in surgical procedures requiring dissection of ... of a quality conduit through a single ...
Medicine Products: